What is a major limitation of nuclear scintigraphy in bone tumor staging?

• A. Lacks specificity: detects active bone turnover & hyperemia broadly.
• B. Provides precise tumor margins
• C. Is cheaper than radiography
• D. Is unaffected by tumor biology

Answer: (A)

The main concept is that nuclear scintigraphy is highly sensitive for detecting areas of bone turnover, but it lacks specificity for identifying neoplastic tissue. The radiotracer used accumulates in regions with increased osteoblastic activity and blood flow, which includes not only tumor-related bone remodeling but also healing fractures, infections, arthritis, and other inflammatory or reactive processes. Because of this broad activation, a “hot spot” on a bone scan cannot distinguish malignant bone tumors from these other causes, making it a poor stand-alone tool for definitive tumor characterization or margin assessment. It’s useful for a whole-body survey to screen for multifocal disease, but confirmatory imaging (CT, MRI) or biopsy is needed to determine exact extent and nature of the tumor. The other options aren’t as accurate: bone scintigraphy does not provide precise tumor margins (limited spatial resolution and non-specific signal), is not cheaper than radiography, and its uptake is indeed influenced by tumor biology through osteoblastic activity.